Hong Kong–listed Shandong Weigao Group Medical Polymer Company Limited (WEIGAO GROUP) announced that the Hong Kong Stock Exchange (HKEX) has approved the listing and dealing of up to 48.30 million previously unlisted shares as H shares under its Full Circulation program.
The approval, granted on 18 November 2026, clears the way for nine participating shareholders—each operating through Tianjin Yangfan–branded limited partnerships—to convert their unlisted domestic shares into H shares. Post-conversion, these 48.30 million shares will account for approximately 1.06 % of WEIGAO GROUP’s enlarged issued share capital, taking the company’s total H-share count to 4.57 billion and lifting the proportion of H shares to 100 % of shares outstanding.
Key allocation details: • Largest allocation: Tianjin Yangfan No. 1 Enterprise Management Consulting Partnership at 7.45 million H shares (0.16 %). • Smallest allocation: Tianjin Yangfan No. 6 Enterprise Management Consulting Partnership at 4.75 million H shares (0.10 %). • Each of the remaining seven partnerships will hold between 4.80 million and 5.70 million H shares, representing 0.11 %–0.12 % stakes apiece.
Prior to the conversion, WEIGAO GROUP’s share capital comprised 48.30 million unlisted shares (1.06 %) and 4.52 billion H shares (98.94 %). Following completion, all 4.57 billion shares will trade as H shares on HKEX, eliminating the unlisted share class.
The company will proceed with the requisite registration and listing formalities and intends to release further updates in line with Hong Kong’s disclosure requirements. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.
Comments